Siemens teams for real time Covid-19 test

Siemens teams for real time Covid-19 test
Technology News |
Siemens Healthineers is looking at developing a real-time biosensor test for Covid-19 using Cardea Bio's Biosignal Processing Unit (BPU) platform.
By Nick Flaherty

Share:

The health technology arm of Siemens has teamed up for the next generation of real time electronic Covid-19 test

The deal with Cardea Bio in San Deigo will see the Siemens Healthineers’ Centre for Innovation in Diagnostics (CID) looking at developing real-time biosensor applications using Cardea’s Biosignal Processing Unit (BPU). According to Cardea, the BPU is the first and only semiconductor capable of translating real-time streams of ‘multiomics’ multichannel signals into digital information and the company is the world’s only mass producer of a biocompatible semiconductor.

The technical teams from Siemens Healthineers and Cardea will work on optimizing and testing the capabilities of a next generation SARS-CoV-2 immunoassay. This includes transferring hardware, software, ‘wetware’ and know-how to Siemens Healthineers facilities to experiment with Cardea’s BPU platform.

Many companies are working on faster Covid-19 tests, from Bosch in Germany and DNANudge in the UK speeding up PCR testing time with automated systems to imec with a breath test for the virus.

Related articles

If successful, Siemens Healthineers and Cardea have ambitions to potentially expand their collaboration to other areas which may include simultaneous measurement of antigen and amplification-free RNA detection to combine the sensitivity of PCR tests with the speed of immunoassays in a single test.

“We’re very humbled and proud that Siemens Healthineers has identified the transformational capabilities that our BPU Platform can bring to several areas across their existing and future product portfolios, and we look forward to the opportunity of realizing the potential of our technology together with the impressive team at Siemens Healthineers that has product development and marketing capabilities like few others in the world,” said CEO of Cardea, Michael Heltzen.

“Our commercial partners will allow the world to see the immediate benefits of Cardea’s BPU Platform now and in the years to come. Our BPUs are not siloed to any one industry and the ultimate goal of this project together with Siemens Healthineers is creating a multiomics diagnostic platform for point-of-care use cases,” said Chief Business Officer at Cardea, Rob Lozuk.

www.siemens.com; www.cardeabio.com

Related articles

Other articles on eeeNews Europe

Linked Articles
eeNews Europe
10s